Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2008 1
2009 3
2010 7
2011 5
2012 4
2013 6
2014 2
2015 6
2016 3
2017 3
2018 6
2020 4
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: oeda t. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.
Pharmacological interventions for anxiety in Parkinson's disease sufferers.
Sawada H, Umemura A, Kohsaka M, Tomita S, Park K, Oeda T, Yamamoto K. Sawada H, et al. Among authors: oeda t. Expert Opin Pharmacother. 2018 Jul;19(10):1071-1076. doi: 10.1080/14656566.2018.1485650. Epub 2018 Jun 25. Expert Opin Pharmacother. 2018. PMID: 29939821 Review.
Low body mass index and life prognosis in Parkinson's disease.
Park K, Oeda T, Kohsaka M, Tomita S, Umemura A, Sawada H. Park K, et al. Among authors: oeda t. Parkinsonism Relat Disord. 2018 Oct;55:81-85. doi: 10.1016/j.parkreldis.2018.05.011. Epub 2018 May 15. Parkinsonism Relat Disord. 2018. PMID: 29784560
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: oeda t. Mult Scler Relat Disord. 2022 Apr;60:103730. doi: 10.1016/j.msard.2022.103730. Epub 2022 Mar 7. Mult Scler Relat Disord. 2022. PMID: 35287025 Free article. Clinical Trial.
49 results